A popular diabetes and weight loss drug could be on the horizon in pill form as drugmaker Eli Lilly released results of an experimental GLP-1 phase three trial.

Mounjaro, which is marketed to treat Type 2 diabetes, and Zepbound, which is intended to treat obesity, are used as injectable medications. But they could soon be administered in pill form, Eli Lilly said.

The once-daily pill helped people lower their weight by an average of 12% after 72 weeks, which amounts to more than 27 pounds. The study involved more than 3,000 adults who had obesity or were overweight and had at least one weight-related health problem.

The results have not yet been peer-reviewed.

"Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes," said Kenneth Custer, exec

See Full Page